VYNE Therapeutics Inc. (VYNE) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
VYNE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VYNE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 96.0% | -5219.1% | -4646.1% |
| 2024 | 100.0% | -8710.0% | -7950.9% |
| 2023 | 100.0% | -6900.5% | -6710.4% |
| 2022 | 100.0% | -7189.7% | -4865.8% |
| 2021 | 100.0% | -4179.5% | -7876.4% |
Download Data
Export VYNE earnings history in CSV or JSON format
Free sign-in required to download data
VYNE Therapeutics Inc. (VYNE) Earnings Overview
As of May 8, 2026, VYNE Therapeutics Inc. (VYNE) reported trailing twelve-month net income of -$26M, reflecting +34.0% year-over-year growth. The company earned $-0.62 per diluted share over the past four quarters, with a net profit margin of -4646.1%.
Looking at the long-term picture, VYNE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2015.
VYNE Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including DERM (-$9M net income, -26.1% margin), PRGO (-$1.82B net income, -33.5% margin), SKIN (-$6M net income, -3.2% margin), VYNE has room to improve margins relative to the peer group. Compare VYNE vs DERM →
VYNE Earnings vs Peers
Earnings metrics vs comparable public companies
VYNE Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$26M | +33.5% | -$30M | $-0.62 | -4646.1% | -5219.1% |
| 2024 | -$40M | -40.0% | -$44M | $-0.94 | -7950.9% | -8710.0% |
| 2023 | -$28M | -22.6% | -$29M | $-2.77 | -6710.4% | -6900.5% |
| 2022 | -$23M | +68.3% | -$34M | $-10.65 | -4865.8% | -7189.7% |
| 2021 | -$73M | +71.3% | -$39M | $-25.65 | -7876.4% | -4179.5% |
| 2020 | -$256M | -262.7% | $253M | $-141.90 | -1217.4% | 1203.0% |
| 2019 | -$70M | -37.0% | -$76M | $-149.48 | -15906.1% | -17210.4% |
| 2018 | -$51M | -76.9% | -$55M | $-170.94 | -483.5% | -512.5% |
| 2017 | -$29M | -106.7% | -$30M | $-101.65 | -634.6% | -645.9% |
| 2016 | -$14M | -205.3% | -$14M | $-46.49 | -2087.2% | -2126.4% |
See VYNE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VYNE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VYNE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVYNE — Frequently Asked Questions
Quick answers to the most common questions about buying VYNE stock.
Is VYNE growing earnings?
VYNE EPS is $-0.62, with earnings growth accelerating to +34.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-26M.
What are VYNE's profit margins?
VYNE Therapeutics Inc. net margin is -4646.1%, with operating margin at -5219.1%. Below-average margins reflect competitive or cost pressures.
How consistent are VYNE's earnings?
VYNE earnings data spans 2015-2025. The accelerating earnings trend is +34.0% YoY. Historical data enables comparison across business cycles.